Podcasts about mounjaro

Ti promettono meno fame.Ti promettono una perdita di peso rapida.Ti promettono una soluzione che fino a pochi anni fa sembrava impossibile.E per molti versi mantengono la promessa.Ozempic, Wegovy, Mounjaro e i nuovi farmaci per il dimagrimento stanno cambiando il modo in cui milioni di persone affrontano il problema del peso.La bilancia scende, l'appetito si riduce e per la prima volta molte persone riescono a ottenere risultati che sembravano irraggiungibili.Ma c'è una domanda che quasi nessuno si pone.Qual è il conto da pagare?Perché ogni volta che una soluzione sembra troppo semplice, vale la pena fermarsi un attimo e guardare cosa succede dietro le quinte.In questo episodio del podcast Vivere in Chetogenica, il Dott. Lorenzo Vieri affronta il lato meno raccontato dei farmaci GLP-1 come Ozempic, Wegovy e Mounjaro.Non per demonizzarli. Non per creare paura. Ma per riportare equilibrio in una conversazione che spesso racconta solo una parte della storia.Parleremo degli effetti collaterali gastrointestinali che molte persone sperimentano, della nausea, della stitichezza, delle difficoltà digestive e della gestione dell'alimentazione durante il trattamento.Ma soprattutto parleremo di ciò che rischia di diventare il vero problema dei prossimi anni: la perdita di massa muscolare.Perché perdere peso non significa automaticamente migliorare la propria salute.Se il peso perso arriva in parte dai muscoli, il metabolismo ne paga il prezzo.E quel prezzo può manifestarsi proprio nel momento in cui il farmaco viene sospeso.Affronteremo inoltre il tema del costo economico, della difficoltà di interrompere queste terapie, del rischio di recuperare il peso perso e di una verità che spesso viene dimenticata: nessuna puntura può sostituire un cambiamento reale delle abitudini.Il farmaco può essere uno strumento.Ma non può diventare il progetto.E se durante il percorso non costruisci nuove competenze, nuove abitudini e un nuovo rapporto con il cibo, il rischio è quello di ritrovarti esattamente dove eri partito.Con qualche chilo in meno oggi.E molti più problemi domani.

Why aren't there more medical insurance plans that cover alternative medicine? Solutions for Long Covid; MK7 vitamin K slows arterial calcification; Keto diet shows promise for treatment of anorexia; It's not so much salt restriction—it's the dietary sodium/potassium ratio in hypertension; Study finds multivitamins don't keep you from getting Covid—but when you get it, it's milder; Incidence of social anxiety disorder is soaring among young people.

If I could go back and start my GLP-1 journey all over again, there are a lot of things I would do differently.Not because I regret taking a GLP-1—but because there were lessons I had to learn through experience that I wish someone had told me from the very beginning.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 user Gianna Beasley shares the biggest things she wishes she knew before starting Ozempic, Wegovy, Mounjaro, and GLP-1 medications, including the nutrition, mindset, and lifestyle lessons that made the biggest difference.We're covering:The mistakes I made early in my GLP-1 journeyWhy protein matters more than most people realizeThe importance of hydration and side effect managementWhy I wish I focused less on the scale and more on strengthThe mental health and mindset work I wish I had done soonerWhy comparison is one of the fastest ways to sabotage your progressWhat actually matters for long-term success on a GLP-1The advice I would give myself if I were starting over todayWhether you're considering a GLP-1, just getting started, or have been taking one for a while, this episode will help you avoid common pitfalls and focus on what truly supports your health and success.

Professor Donal O'Shea, specialist in obesity, responds to the National Centre for Pharmacoeconomics comments that Mounjaro could be deemed cost effective.

Apply for coaching

A few years ago, I came across a quote that said:"I think the key to a happy life as an adult woman is to channel your inner weird little girl and make her happy."It immediately resonated with me.I was the kid making potions in the yard, obsessed with magic books, fortune tellers, mood rings, crystals, and all things mystical. And the older I get, the more I realize those parts of me never disappeared—they just got buried under adulthood and responsibility.In this episode, I'm talking about whimsy—not as a trend, but as a way of reconnecting with yourself. I'm sharing what's on my whimsical summer list, why I've been intentionally making more room for wonder, and how this connects to one of the core principles of Irresistible You: Feed Your Soul.Because maybe creating a magical life isn't about becoming someone new.Maybe it's about remembering who you've been all along. ✨

Ozempic, Wegovy and Mounjaro can help people lose weight. But what should you eat on GLP-1 drugs to avoid side effects, protect muscle, and maintain results long term? In this episode, Dr Federica Amati, ZOE's Head Nutritionist and author of The Appetite Reset, explains how these drugs work, why many people struggle with side effects, and why losing weight does not automatically mean better health. You'll learn why the weight lost may not be fat, why nutrient deficiencies, dehydration and muscle loss can become a risk, and what to eat before, during and after treatment. Federica shares four practical principles to help reduce side effects, protect lean mass, improve diet quality and support long-term health whether you stay on these medications or eventually stop taking them. Millions of people are now using GLP-1 drugs. But if these medications reduce appetite so effectively, how do you make sure your body still gets the nutrients it needs?

The GLP-1 conversation has completely changed the wellness world. What started as a diabetes medication is now being talked about for weight loss, metabolism, cravings, inflammation, and even longevity.But as more people jump on medications like Ozempic, Wegovy, and Mounjaro, some important questions are getting overlooked. .  .Today, we're talking about:The hidden mistake that could make your weight loss backfireWhy some people lose more than just body fat, but lean tissueThe nutrient strategy experts say becomes even more important on GLP-1 medicationsThe surprising symptom many people can blame on the medication itself (but could not be)How to protect your metabolism while losing weightNatural ways to support your body's own GLP-1 productionThe connection between your gut bacteria, appetite, and cravingsWhy sleep may be playing a bigger role than you realizePlus . . . today's feelgood thing.Big thanks to our sponsor, ITL Health.More information on their magnesium formulations, designed with bioavailability in mind, can be found here:https://itlhealth.ca/Thank you for being a part of this space! xo

This episode explores how to use GLP-1 medications like semaglutide/Ozempic and tirzepatide/Mounjaro safely and effectively. Dr. Mike Hart and Dr. Christle Guevarra Do discuss once-weekly dosing, individualized titration, optimal dose selection, food noise, appetite suppression, and the risks of dosing mistakes with vials or gray-market peptides. They also cover why resistance training, protein, fiber, and realistic nutrition habits are essential for preserving muscle and maintaining results. The conversation expands into GLP-1 benefits beyond weight loss, including cardiovascular protection, inflammation, autoimmune flares, addiction-related behaviors, alcohol cravings, libido, menstrual cycles, PCOS, sleep apnea, and what to expect when stopping the medication. Dr. Christle Guevarra Do is a physician focused on obesity medicine, GLP-1 education, weight management, and sustainable lifestyle change. Drawing from both her clinical experience and her own long-term use of GLP-1 medication, she helps patients understand how these medications fit into the bigger picture of long-term health. Her approach emphasizes individualized care, strength training, nutrition, behavior change, and realistic maintenance strategies rather than quick fixes. In this episode, she shares practical guidance for using GLP-1s responsibly while protecting muscle, managing hunger, and building habits that support lasting results. Dr. Christle Guevarra Website https://www.drchristle.com/ Dr. Christle's Free GLP-1 Guide https://www.drchristle.com/glp1-guide Dr. Christle Instagram https://www.instagram.com/dr.christle/ Ozempic — semaglutide https://www.ozempic.com/ Wegovy — semaglutide for weight management https://www.wegovy.com/ Mounjaro — tirzepatide https://mounjaro.lilly.com/ Zepbound — tirzepatide for weight management / sleep apnea https://zepbound.lilly.com/ FDA: Concerns With Unapproved GLP-1 Drugs https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Retatrutide Clinical Trial Info https://clinicaltrials.gov/study/NCT05882045 Vyvanse — lisdexamfetamine https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad Creatine — NIH Supplement Info https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional/ Psyllium Husk / Fiber — MedlinePlus https://medlineplus.gov/druginfo/meds/a601104.html Berberine — NCCIH https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know Tesamorelin — MedlinePlus https://medlineplus.gov/druginfo/meds/a611035.html CJC-1295 — PubMed Research https://pubmed.ncbi.nlm.nih.gov/16352683/ Ipamorelin — PubMed Research https://pubmed.ncbi.nlm.nih.gov/9849822/ FDA: Peptides / Compounding Safety Concerns https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Oura Ring https://ouraring.com/ White Claw https://www.whiteclaw.com/   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:45 Weekly Dosing Debate 03:41 Starting Dose Basics 06:28 Pens vs Vials Safety 08:37 Finding Your Sweet Spot 11:01 Nighttime Binge Window 13:32 Lifestyle Work Still Matters 14:30 Benefits Beyond Weight 17:27 Libido and Low Calories 22:26 Alcohol Hits Different 24:59 Cancer Claims Reality Check 26:59 Strength Training Priority 29:06 Supplements and Creatine 29:38 Creatine Protein Fiber Basics 31:50 Berberine Pros and Cons 32:37 Peptides Sleep and Muscle 35:28 Too Lean for GLP-1 38:52 Cycles PCOS and Fertility 40:45 Food Noise vs Appetite 44:42 Staying On or Stopping 49:19 Heart Rate and HRV Concerns 51:38 Ozempic vs Mounjaro Choices 54:45 Sleep Apnea and Wrap Up The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

¿La metformina sirve para bajar de peso? ¿Es un tratamiento para toda la vida? ¿Y qué diferencia tiene con medicamentos como Ozempic, Wegovy o Mounjaro? En este episodio hablamos sobre qué es la metformina, cómo funciona realmente dentro del cuerpo, quiénes podrían beneficiarse de su uso y cuáles son sus efectos secundarios más frecuentes. También aclaramos algunas de las dudas más comunes sobre resistencia a la insulina, prediabetes, diabetes tipo 2 y pérdida de peso, además de revisar cuándo puede ser una herramienta útil y cuándo no necesariamente es la mejor opción. Si actualmente utilizas metformina o te la han recomendado recientemente, este episodio te ayudará a entender qué sí puedes esperar de este medicamento y qué aspectos vale la pena revisar para acompañar mejor tu tratamiento.

Former Navy SEAL Team 6 operator Craig "Sawman" Sawyer — founder of the nonprofit Veterans for Child Rescue — joins Mike Vera on the Healthy & Awake Podcast to share his firsthand assessment of child trafficking in America: how he says it operates, why he believes it stays out of the headlines, and what he argues regular people can do about it. One of the heavier conversations we've had on the show, and one of the most important.

O Grupo SmartFit se tornou um negócio multibilionário, com mais de 2 mil unidades em 16 países e um modelo de negócios que está transformando o mercado de fitness e bem-estar.Neste episódio do Economia & Negócios, Patricia Chaccur e José Inácio Pilar conversam com Cristina Duclos, CMO Global do Grupo SmartFit, sobre a estratégia por trás da expansão acelerada da empresa, o posicionamento das suas diferentes marcas, o papel da tecnologia e da inteligência artificial na experiência dos alunos e a evolução do fitness para um ecossistema completo de wellness.A executiva também explica por que as canetas emagrecedoras não estão reduzindo a demanda por academias, como a geração Z está mudando a relação com atividade física e por que a SmartFit quer se tornar uma das marcas mais admiradas do Brasil.Entre os temas da entrevista:Como o Grupo SmartFit ultrapassou 2 mil academias em 16 paísesA estratégia de expansão internacional do grupo - O posicionamento das marcas SmartFit, Bioritmo, Nation CT, Velocity e Vidya StdudioInteligência artificial aplicada ao fitness e ao atendimentoO impacto de Ozempic e Mounjaro no mercadoWellness, longevidade e saúde socialO futuro das academias nos próximos anosApoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay:  https://assine.oantagonista.com.br/  Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br #SmartFit #EconomiaENegocios #SucessoEmpresarial #ModeloDeNegocios #Ozempic #GeracaoZ #TecnologiaEHealth #AcademiaSmartfit #MercadoFitness #Empreendedorismo

This week it's just Steven and Devon holding down the fort while Ben is away, which means the conversation somehow manages to jump from guitar maintenance to Star Wars collectibles to post-apocalyptic murder mysteries without missing a beat. Real Life Devon spent part of the week giving some attention to an old Kelly-style guitar that had been fighting him for years. After wrestling with the floating tremolo system, he explains the joys and frustrations of guitar intonation and why getting everything properly adjusted can feel more like engineering than music. With the guitar finally behaving itself, he's been spending time learning Vivaldi's Summer, proving once again that classical music can be every bit as metal as heavy metal. Meanwhile, Steven returned from a Disney trip with a collection of souvenirs that may or may not require their own dedicated shelf. The haul includes a Spira gift card, a BB-series droid, a C-series droid head popcorn bucket, a Grand Holocron, a new Star Wars font hat, and nearly every Kyber crystal available. Unfortunately, despite collecting the entire rainbow, none of the elusive secret crystals made their way home. Such is the way of the Force. Future or Now Devon dives into Paradise on Hulu, starring Sterling K. Brown. What initially appears to be a political thriller quickly reveals itself to be something much stranger. Without spoiling too much, the series combines a whodunit mystery with a post-apocalyptic setting and some surprisingly deep character development. The show's vision of "The American Dream Underground" becomes one of the most fascinating aspects of the story, and Devon argues that the character work is what truly elevates the series above similar mystery shows. The conversation also briefly touches on Hoppers, now available on Disney+. The verdict? It's definitely strange. Whether that strangeness is good or bad may depend entirely on your tolerance for Pixar-style weirdness. There may also be connections to the Pixar Theory, but there simply isn't enough time to open that particular can of worms. Steven brings an interesting study examining the real-world effects of popular GLP-1 weight-loss medications like Ozempic, Wegovy, Mounjaro, and Zepbound. Researchers analyzing Fitbit data discovered that while patients successfully lost weight after starting the medications, many also became less physically active. Daily step counts and exercise levels declined, raising concerns because these drugs can reduce muscle mass alongside fat loss. The findings highlight an important reminder: losing weight and maintaining physical fitness aren't necessarily the same thing, and preserving strength remains a critical part of long-term health. Links Paradise (IMDb): https://www.imdb.com/title/tt27444205 Weight-loss medication activity study: https://www.sciencedaily.com/releases/2026/06/260614011841.htm   This episode covers everything from guitar maintenance and Disney loot to dystopian mysteries and the surprising relationship between weight loss and physical activity. Just another normal week on Science Faction.

Inside the venom of a desert lizard, scientists found a molecule that does something the diet industry spent 50 years failing to do. It quietly switches off hunger. That molecule is now the most talked about drug on the planet, and it's sitting in the fridges of millions of people who couldn't explain how it works if you paid them.Dr Tom Buckley, 30 years in medicine and a professor at Sydney University, has looked at the evidence and called these drugs revolutionary.But what about "Ozempic face"? What if the wait comes back after you stop? Who should never touch these drugs? Dr Tom and Andrew get into the science so you finally have all the answers you need. 00:00 – A desert lizard that eats twice a year 03:32 – What a GLP-1 actually is, in plain English 07:36 – Ghrelin and leptin: hunger and fullness, explained 10:23 – The venom that cracked the hunger code 14:06 – Why your body is built to hold onto fat 15:19 – How to raise GLP-1 without a prescription 18:10 – Become the CEO of your body and brain 22:10 – You don't lose fat cells, they shrink 24:39 – "Ozempic face," and why you lose weight slowly 28:17 – The "Limitless" effect: cognitive horsepower 29:28 – 76 trials, 40,000 patients: the evidence 30:47 – Lancet 2024: heart attacks and strokes down 32:11 – Why Tom calls these drugs regenerative 34:18 – Who should never take it 35:23 – The side effects nobody mentions upfront 41:19 – On it and off it: what you have to get right 48:14 – Most regain 75% within a year of stopping 50:09 – Metabolic rebound: worse than where you started 52:51 – The hidden economy GLP-1s are reshaping 56:13 – Tom's cliff notesYou can find Dr Tom at his LinkedIn: https://www.linkedin.com/in/tom-buckley-06a76b98/ Use Code "PQPODCAST10" to get 10% off your Lumo Coffee order:https://lumocoffee.com/ Interested in sharing your story? Email Producer Shannon at support@performanceintelligence.com today with your story and contact details. Learn more about Andrew and Performance Intelligence: https://performanceintelligence.com/Find out more about Andrew's Keynotes : https://performanceintelligence.com/keynotes/Follow Andrew May: https://www.instagram.com/andrewmay/Watch the Performance Intelligence Podcast on Youtube: https://www.youtube.com/@performanceintelligencepodcastIf you enjoy the podcast, we would really appreciate you leaving a short review on Apple Podcasts, Spotify or Google Play. It takes less than 60 seconds and really helps us build our audience and continue to provide high quality guests.

Niamh emails in raging about the amount of people taking “fat jabs” like Ozempic and Mounjaro, calling them the “lazy way out” and saying weight loss should be done the old-fashioned way — diet and exercise.Adrian argues it's nobody's business how someone loses weight, once they're healthier. Jeremy isn't having it, saying people don't deserve praise if “the jab did the work”.Stay listening for the awkward moment when Jeremy is called out by a colleague.

Ils s'appellent Ozempic ou encore Mounjaro : ces médicaments injectables vendus pour perdre du poids rapidement font fureur dans de nombreux pays, notamment aux États-Unis, mais aussi au Brésil. Destinés normalement aux cas d'obésité ou de diabète, un grand nombre de Brésiliens en prend aujourd'hui, parfois sans prescription médicale. 5 000 euros pour perdre 22 kilos. C'est ce qu'a annoncé un endocrinologue très populaire sur les réseaux sociaux à Clara Varandas. À 31 ans, cette architecte a finalement perdu 12 kilos en quatre mois. Elle prenait une version « sur mesure » de la tirzépatide. Mais en même temps qu'elle maigrissait, elle sentait son corps s'affaiblir. « J'ai été très malade, des problèmes affreux que je n'avais jamais eus auparavant. Par exemple, j'ai eu une infection bactérienne de la peau, sur le visage. J'ai eu un côté du visage très gonflé à cause d'une simple piqûre de moustique », explique-t-elle. Chaque semaine, elle se rendait dans ce cabinet d'un quartier chic de Sao Paulo. Très chers, ces médicaments font aussi l'objet de contrebande au Brésil, raconte la correspondante de RFI, Sarah Cozzolino. Ce qui multiplie les risques d'effets secondaires indésirables, et parfois graves. Un mois d'injections de Mounjaro, acheté en pharmacie, vaut entre 200 et 350 euros. C'est plus que le salaire minimum au Brésil. À Rio de Janeiro, dans la favela de Maré, un équivalent paraguayen du médicament circule. Ce vendredi soir, Matheus Euzébio et une de ses amies s'appliquent eux-mêmes la dose, achetée dans une clinique clandestine. « Au début, ce n'était que pour les riches, témoigne-t-il dans le reportage de Sarah Cozzolino, mais maintenant on peut s'en procurer facilement pour pas cher ».    Le secrétaire général de l'ONU en visite en Haïti Antonio Guterres se rend pour la seconde fois en Haïti. Il doit se rendre notamment dans un camp de déplacés à Port-au-Prince et « constater l'aggravation de la situation sécuritaire », précise Gotson Pierre, de l'agence Alterpresse. De son côté, « la Commission pastorale pour la justice et les droits humains lance un appel à une prise de conscience nationale sur la situation des enfants », particulièrement exposés à la violence et la précarité dans le pays, ajoute-t-il. Enfin, Alterpresse évoque l'inquiétude des partis signataires de l'accord du Montana : le décret électoral publié le 2 juin 2026 n'est pas conforme à la Constitution, estiment-ils, remettant en cause également la légitimité légale du maintien au pouvoir du Premier ministre de transition Alix Didier Fils-Aimé.   Les États-Unis assurent avoir livré 300 « criminels » au Mexique 313 personnes ont été livrées par Washington à la justice mexicaine depuis le retour de Donald Trump à la Maison Blanche, a assuré ce lundi 15 juin 2026, l'ambassadeur des États-Unis au Mexique, dans un message publié sur les réseaux sociaux. Est-ce un pas vers Mexico, alors que la question des extraditions est devenue, ces dernières semaines, un sujet de fortes tensions diplomatiques entre les deux pays ? Explications avec Justine Fontaine.   Dans le journal de La 1ère... Six Amérindiens (des peuples Kali'na et Arawak) de Guyane décédés à la fin du XIXème siècle à Paris seront bientôt de retour sur leurs terres, explique Benoît Ferrand, d'Outre-mer La 1ère. 

For millions of people living with obesity, weight loss drugs have been hailed as a game changer.They're known as GLP-1s but are more commonly known by their trade names: Ozempic, Wegovy and Mounjaro. So far they've only been made by two companies in Denmark and the US and they're pretty expensive. But now the patents for these drugs have expired in China and India, which means pharmaceutical companies in those countries can now make cheaper copies. India has a reputation as the "pharmacy of the world" because of its ability to turn expensive medicines into affordable mass-market products. The country is the world's largest supplier of generic medicines. Indian companies are already starting to produce and sell these weight loss drugs. So what impact will this have on the cost and supply of weight loss drugs in India and around the world? Archana Shukla, the BBC's India business correspondent in Mumbai, tells us why the expiry of the patents is such a big deal. And BBC Health correspondent James Gallagher explains how these drugs work. Instagram: @bbcwhatintheworld Email: whatintheworld@bbc.co.uk WhatsApp: +44 330 12 33 22 6 Presenter: Hannah Gelbart Producers: Chelsea Coates, Julia Ross-Roy and Benita Barden Video Producer: Baldeep Chahal Editor: Verity Wilde

Worried about gaining weight back after Ozempic, Wegovy, Mounjaro, or Zepbound?You're not alone. One of the biggest concerns people have during their GLP-1 journey is what happens after the weight loss phase—and how to actually maintain their results long-term.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what sustainable weight maintenance really looks like, why maintaining weight loss is different from losing weight, and the habits that support long-term success.Because keeping weight off isn't about being perfect. It's about building routines that you can realistically maintain for years to come.We're covering:Why weight maintenance is different than weight lossCommon reasons people regain weight after losing itThe role of appetite, food noise, and long-term behavior changeWhy protein and strength training matter for maintenanceHow muscle supports long-term health and weight managementThe mindset shifts that make maintenance easierWhy all-or-nothing thinking keeps people stuckWhat successful long-term maintenance actually looks likeWhether you're currently taking Ozempic, Wegovy, Mounjaro, or Zepbound—or simply thinking ahead to the future—this episode will help you focus on the habits that support lasting results.

In Part 2 of this series, we're diving into the practical nutrition strategies that can help you feel your best while taking medications like Ozempic, Mounjaro, and Zepbound.From constipation and digestive changes to hitting your protein goals with a low appetite, this episode focuses on the habits that support long-term success and help you maintain your results. We'll cover:• Why constipation is so common on GLP-1 medications and how to prevent it• How to reach your protein goals when you get full quickly• What to do when protein foods don't sound appealing• How GLP-1 medications change hunger and fullness cues• What to expect if you need to temporarily stop your medicationGLP-1 medications can be powerful tools, but they work best when paired with the right nutrition and lifestyle habits. Learning how to fuel your body, support digestion, and adapt to your changing appetite is key to protecting your health while achieving sustainable weight loss.WORK WITH US:O​​ntario-Wide Virtual Obesity Management Clinichttps://www.highmetabolicclinic.comJoin my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweightRecover Strong for Binge Eatinghttps://www.sashahighmd.com/bedTaking the first step toward weight loss can feel overwhelming — but you don't have to do it alone. I've created a curated list of my podcast episodes to gently guide you as you begin your journey. https://www.sashahighmd.com/podcast-guide

GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured:  Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University 

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

Negotiations between pharmaceutical giant Eli Lilly and the Australian government have broken down over adding the blockbuster diabetes and obesity drug Mounjaro to the PBS. Dr Gabrielle Reppen joins James Willis. See omnystudio.com/listener for privacy information.

Linktree for Community ResourcesNeed help appealing a GLP-1 Insurance Denial? FindHonestCare.com/KimRo - Telehealth for GLP1 Weight ManagementThe Absolute Lies You've Heard About GLP-1s (Ozempic Myths Debunked) [REPLAY]Are you being lied to about Ozempic, Mounjaro, and Wegovy? In this special replay episode, leading obesity medicine specialists break down the biggest GLP-1 myths taking over your feed. We are reposting this crucial conversation because it is more relevant than ever. With GLP-1 price changes and expanding access options through federal programs like the Medicare GLP-1 Bridge, understanding the real science behind these medications is essential for patient advocacy.We are sharing a few favorite replay episodes right now while Kim is away on bereavement leave following the loss of her sister. We want to deeply thank our subscribers for staying engaged and supporting the show during this time.In this episode of The Plus Sidez Podcast, Kat joins Kim to sit down with obesity medicine specialists Dr. Matea Rentea and Dr. Ali Novitzki to help listeners better understand their disease and feel empowered in their healthcare journey.The Myths We Debunk:The Muscle Loss Scare: The data behind weight loss and body composition, explaining why the medication itself is not destroying your lean mass.The Willpower Narrative: Why obesity is a genetic, chronic metabolic disease rooted in brain biology, not a failure of personal willpower.The Shot-Only Illusion: How the medication works alongside your body's natural satiety signals and gut receptors.Obesity Doctor Guidance Shared:Metabolic Protection: A practical discussion on utilizing a 10-minute fitness routine and a 100-gram protein framework to maintain lean mass and support insulin sensitivity.System Navigation: Insights on navigating insurance barriers, managing prior authorizations, and advocating for proper medical care.Mental Resilience: Tools to process unsolicited comments about your weight and protect your peace from societal judgment.Episode Topics:Why We Are Replaying This Episode: Prices, Access, and UpdatesThe Insurance Landscape: Understanding Prior AuthorizationsMeet the Obesity Medicine SpecialistsDeconstructing the GLP-1 Muscle Loss NarrativeStrategies for Protecting Your MetabolismWhat the Scales Do Not Show About Insulin ResistanceNatural Satiety Triggers and Gut ReceptorsRecognizing Obesity as a Biological Chronic DiseaseAddressing Weight Stigma and External CommentarySubscribe to The Plus Sidez Podcast for science-backed episodes breaking down metabolic health, body recomposition, and the truth about weight loss.Search TagsGLP1 lies debunked, Ozempic myths, Mounjaro weight loss journey, Wegovy truth, Zepbound body recomposition, insulin sensitivity hacks, natural GLP1 boosters, treating obesity metabolic disease, plus sidez podcast, dr matea rentea, dr ali novitzki_________________________________________________________________________Join this channel to get access to perks:https://www.youtube.com/channel/UC0HUIGKl3BN4Vg6LYI-dkOA/join_________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovySend us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

GLP-1 stopped working? Or is your body trying to tell you something deeper?In this episode, Kylie unpacks the REAL reason so many women hit a weight loss plateau while taking Ozempic, Mounjaro, Semaglutide or Tirzepatide… and why the answer is NOT always “eat less” or “increase your dose.”You'll learn: • Why GLP-1 plateaus happen • The hidden danger of losing muscle while dieting • How chronic stress and cortisol can stall fat loss • Why blood sugar regulation matters more than calories alone • The truth about “metabolic damage” • How under-eating protein can slow your progress • Why your nervous system affects the scale more than you think • The biggest mistakes women make when their appetite drops • How to support your metabolism WITHOUT spirallingThis episode is a must-listen for women over 40 who feel frustrated, stuck, inflamed, exhausted, or scared that their body has “stopped responding.”Because your body isn't broken, babe. It's adapting.And once you understand what's really happening beneath the surface… everything changes.

One of the biggest questions people ask about GLP-1 medications is:“What happens if I stop taking it?”Whether you're taking Ozempic, Wegovy, Mounjaro, or Zepbound, you may have concerns about losing insurance coverage, reaching your goal weight, medication costs, long-term use, or the possibility of regaining weight in the future.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what the research actually shows about stopping a GLP-1 medication, the factors that influence weight regain, and what you can start doing now to support long-term success.We're covering:What happens when you stop a GLP-1 medicationWhether weight regain is inevitableWhy hunger and food noise may change after discontinuationCommon myths about stopping Ozempic, Wegovy, Mounjaro, and ZepboundWhy willpower is not the solutionThe habits that support long-term weight maintenanceWhat to do if you lose access to your medicationHow to think about weight regain without shame or fearIf you've ever worried about what happens after a GLP-1, this episode will help you approach the conversation with more knowledge, less fear, and a realistic plan for the future.

A headline like “weight loss drugs may reduce breast cancer risk” grabs attention fast, but the real story lives in the fine print. We take you through a new Penn Medicine study that observed lower breast cancer rates among women with overweight or obesity who used GLP-1 medications, then we translate what that finding actually means in plain language. Observational data can reveal a signal worth studying, but it cannot prove the medication caused the outcome, and that distinction matters for your decisions and your expectations. We also zoom out to the bigger why: obesity is not just about body size. Fat tissue is biologically active, shaping chronic inflammation, estrogen exposure after menopause, insulin resistance, and even how well the immune system spots abnormal cells. Those pathways help explain why obesity is linked to many cancers, including postmenopausal breast cancer, and why researchers are curious whether effective obesity treatment could shift risk over time. Then we get practical. We review what stronger evidence from randomized controlled trials says so far: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do not appear to increase breast cancer risk in the available trial data, even though most trials were not designed to study cancer outcomes for many years. We also discuss why newer studies seem most suggestive for hormone receptor positive breast cancer, along with the leading theories: weight loss itself, improved metabolic health and insulin signaling, reduced inflammation, and the still-unclear possibility of direct GLP-1 effects in cancer biology. If you like evidence-based medicine with real-world context (and a little Philly-life banter), subscribe, share this episode with a friend, and leave a review so more people can find the show. What question do you want answered next about GLP-1s, obesity treatment, or cancer risk?ReferencesRisk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-Analysis. Ko A, Chang YC, Bahar F, et al. Annals of Internal Medicine. 2025;. doi:10.7326/ANNALS-25-02237.Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis. Piccoli GF, Mesquita LA, Stein C, et al. The Journal of Clinical Endocrinology and Metabolism. 2021;106(3):912-921. doi:10.1210/clinem/dgaa891.Glucagon-Like Peptide 1 Receptor Agonists and Cancer Risk: The Good, the Bad and the Unknown. Mannucci E, Dicembrini I. Nature Reviews. Clinical Oncology. 2026;23(6):459-470. doi:10.1038/s41571-026-01135-0.GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. McDonald ES, Gillis LB, Gabriel P, et al. JCO Oncology Practice. 2026;:101200OP2600485. doi:10.1200/OP-26-00485.GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.. Shah Z, Hundal J, Afridi S, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):10548. doi:10.1200/JCO.2026.44.16_suppl.10548.Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. Tatum KL, Dahman B, Stevenson A, et al. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.Association of Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cancers-Evidence From a Drug Target Mendelian Randomization and Clinical Trials. Sun Y, Liu Y, Dian Y, et al. International Journal of Surgery (London, England). 2024;110(8):4688-4694. doi:10.1097/JS9.0000000000001514.GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.. Guo Cheng and Amanda Ward. Journal of Clinical Oncology. 2025;43(Suppl 16):10557. doi:10.1200/JCO.2025.43.16_suppl.10557.Glucagon-Like Peptide-1 Analogues and Risk of Breast Cancer in Women With Type 2 Diabetes: Population Based Cohort Study Using the UK Clinical Practice Research Datalink. Hicks BM, Yin H, Yu OH, et al. BMJ (Clinical Research Ed.). 2016;355:i5340. doi:10.1136/bmj.i5340.GLP-1 Receptor Agonists and Cancer: Current Clinical Evidence and Translational Opportunities for Preclinical Research. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. The Journal of Clinical Investigation. 2025;135(21):e194743. doi:10.1172/JCI194743.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Dans cet épisode, je reçois le Docteur Laurent Chevallier, médecin nutritionniste et auteur de Maigrir avec les nouveaux médicaments : révolution ou poison ?, pour parler d'un sujet qui déchaîne les débats depuis quelques années : les médicaments anti-obésité : les fameux GLP-1, Ozempic, Mounjaro. On les entend partout, on voit des stars en faire la promo, et pourtant on comprend rarement ce qu'ils font vraiment dans le corps, à qui ils s'adressent, et ce qu'ils ne règlent pas.Ce qui m'a frappée dans cet échange, c'est à quel point la question du poids est biologiquement complexe, bien au-delà du "mange moins, bouge plus" qu'on entend encore trop souvent.Dans cet épisode, on parle de :Pourquoi il est si difficile de maigrir, et ce que la science dit aujourd'hui sur la mémoire métaboliqueCe que sont vraiment les analogues GLP-1 : leur mécanisme d'action, leur histoire, et pourquoi ils ont d'abord été développés pour le diabèteLes trois effets concrets de ces médicaments : glycémie, estomac, cerveauCe qu'on perd vraiment quand on perd du poids rapidement : muscles, os, micronutrimentsLes carences silencieuses auxquelles faire attention et pourquoi les autres médicaments qu'on prend peuvent aussi être perturbésLes effets secondaires mineurs et les risques plus sérieuxPourquoi les critères actuels de prescription (IMC, poids) sont insuffisants et ce qu'il faudrait regarder à la placeCe qui se passe quand on arrête : les chiffres sur la reprise de poidsLa question des nouvelles formes orales à venir, et pourquoi le Dr Chevallier reste prudentLe rôle des perturbateurs endocriniens, des aliments ultratransformés et du stress dans l'obésitéCe que le Dr Chevallier prescrit vraiment et dans quelles situations précisesPourquoi il défend une médecine de prévention plutôt qu'une médecine de rattrapageEt vous : est-ce que cet épisode change votre regard sur ces médicaments ou sur la question du poids en général ? Dites-le moi en commentaire.Merci à WOJO, notre partenaire qui nous soutient en nous accueillant dans ses magnifiques locaux parisiens de Saint-Lazare !

DC EKG with Joe GroganThe Economics of Ozempic and Other Weight Loss DrugsEpisode 136.5 (“Prescription Refill” – A replay from the archives)Original Air Date: May 2024In this episode, Joe Grogan welcomes Ben Ippolito, Senior Fellow in Economic Policy Studies at the American Enterprise Institute, to discuss the rapidly evolving economics of GLP-1 weight loss drugs like Ozempic and Wegovy.Ben explains the two main competitors in this market—Novo Nordisk's Ozempic and Wegovy versus Eli Lilly's Mounjaro and Zepbound. Revealing how insurance coverage decisions drive pharmaceutical marketing strategy.The conversation reveals a critical irrationality in Medicare policy: the statutory prohibition on covering weight loss drugs despite their profound clinical and quality-of-life benefits. Yet these same drugs are covered for diabetes and cardiovascular risk reduction.Ben explores the surprising economics of drug pricing through gross-to-net pricing—the massive gap between list prices and what insurers actually pay through rebates and discounts.The episode examines critical implications of the Inflation Reduction Act's price negotiation provisions. Once Medicare negotiates Ozempic's price, that same price applies to all products using the same active ingredient. This creates cascading market effects: competitors must match those prices to remain on formularies, new entrants face lower pricing power even if clinically superior, and pharmaceutical companies may abandon promising programs due to regulatory uncertainty.Ben argues Congress doesn't need to act immediately to expand Medicare coverage, but likely will within a few years.Joe and Ben discuss unintended consequences of government price regulation, including effects on innovation and drug development pipelines. They explore how price controls announced before elections affect pharmaceutical strategy and development timelines.Concluding with Ben's research on Medicare Advantage and why both Democrats and Republicans scrutinize this private alternative to traditional Medicare. With over 50 percent of seniors enrolled in Medicare Advantage plans, bipartisan interest in reform is reshaping healthcare policy conversations on Capitol Hill.Key TopicsGLP-1 drugs, Ozempic, Wegovy, Mounjaro, Zepbound, weight loss medications, obesity treatment, Medicare coverage, drug pricing, Inflation Reduction Act, pharmaceutical competition, rebates, gross-to-net pricing, health economics, cardiovascular benefits, diabetes treatment, Medicare Advantage, healthcare policy, innovation incentivesKey Timestamps00:00 Cold Open: "Turned Up to 11"00:24 Welcome to DC EKG00:46 Meet Ben Ippolito (AEI)03:48 The GLP-1 Landscape: Ozempic, Wegovy, and the Field05:04 One Drug, Two Names06:45 Medicare's Weight-Loss Coverage Ban07:21 Blockbusters and Big Effect Sizes09:32 Why Isn't Congress Acting?10:17 Why It Costs Less Than You Think12:34 The Coverage Irrationality14:05 Quality of Life as a Real Benefit15:17 Beyond Weight: Cravings and Addiction18:21 Devil's Advocate: Why Cover It At All?19:48 Gross-to-Net and the Rebate Problem22:41 Why Can't You Just Pay Cash?25:43 The IRA and the Ozempic Price Cut27:32 One Ingredient, One Price30:10 Unintended Consequences in Part D34:01 New Competitors and Killed Programs38:03 What's Next: Medicare Advantage42:04 Wrap-Up and CreditsAbout the Guest(As of May 2024) Ben Ippolito is a Senior Fellow in Economic Policy Studies at the American Enterprise Institute. He holds a PhD and Master's degree in Economics from the University of Wisconsin-Madison and a Bachelor's degree in Mathematics and Economics from Emory University. Ben examines drug pricing policy, Medicare Advantage, and healthcare innovation economics with regular engagement with Congress.Podcast: DC EKG with Joe GroganGuest: Ben IppolitoSponsor: Survivors for SolutionsProducer: Stay on Course StudiosExecutive Producer: John CZ Czwartacki, DC EKG Podcast

Misdiagnosed with Type 2 in her 40s, Claire went into DKA while taking Mounjaro and discovered she actually has Type 1 (LADA). Hear her UK healthcare journey. ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 20% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Nutritionist Leyla Muedin discusses research showing simple strength tests—grip strength and a five-rep sit-to-stand chair test—predict longevity in older women. In a University at Buffalo study of over 5,000 women ages 63–99 followed for eight years, stronger grip and faster chair-stand times were linked to lower mortality; every additional 7 kg of grip strength corresponded to a 12% reduction in death risk, and faster chair-stands were also associated with improved survival, even after adjusting for activity, cardiovascular fitness, and inflammation. She emphasizes prioritizing muscle-strengthening alongside aerobic exercise and suggests accessible resistance options (weights, bodyweight moves, or household items) with professional guidance as needed. She then cites UK Biobank data linking long-term statin use to declines in grip strength and appendicular lean mass, urging discussion with physicians and added vigilance, especially for those also using GLP-1 drugs that may reduce protein intake and muscle mass.

If you're on a GLP-1 and nobody told you how to eat on it, this one's for you. We get into it in depth.Andrea Donsky, nutritionist, bestselling author of Nourishing Menopause, 7x published menopause researcher, menopause educator, and co-founder of wearemorphus.com, sits down with nutrition and fitness coach Natalie Bean, who is GLP-1 certified and has spent 31 years helping people change how they eat. If you're taking Ozempic, Mounjaro, or Wegovy, thinking about it, or you just want to take back control with food, Natalie walks through what actually protects your body. Spoiler: protein is not optional, and the scale is not the whole story.What you'll learn:Why a GLP-1 can cost you 25 to 40 percent of your weight as muscle, and how to push back with foodHow much protein women in perimenopause and menopause really need (and why it climbs on a GLP-1)Whether you'll gain the weight back when you stop, and what a maintenance dose actually doesThe GLP-1 side effects nobody warns you about, from dry mouth to constipation to brittle bonesWhy cardio is not the enemy, and where strength training and cortisol fit inChapters0:00 GLP-1 and muscle loss: the Mayo Clinic stat that stopped me0:48 Meet Natalie Bean and who GLP-1 meds are really for4:45 Food noise, sugar cravings, and insulin resistance after 409:45 Do you gain the weight back after stopping a GLP-1?14:10 How much protein you actually need on a GLP-119:40 GLP-1 side effects: dry mouth, digestion, bones, dehydration25:10 Fiber, constipation, and eating every 2 to 3 hours30:10 Why consistency beats variety when you start over35:10 Cortisol, cardio vs strength, and non-negotiable supplementsListen to this next:Tired of Fighting Food Cravings? Try This Instead: https://youtu.be/2PQxAbnll8sWork with Natalie: https://nutritionforeverinc.com/Send us Fan Mail ======Morphus: Menopause Reimagined

In this episode, I'm talking honestly about weight loss burnout. The mental exhaustion that comes from constantly thinking about food, planning meals, trying to “be good,” starting over, tracking, and feeling like your body is always a project that needs fixing.I also share what this experience has been like for me while being on Tirzepatide. The food noise is quieter, but now I find myself in this strange in-between space where I'm hungry, but nothing sounds good. I take a few bites and feel full… while somehow still feeling hungry at the same time. And honestly? I'm tired.This episode isn't anti-weight loss. It's about what happens when your entire life starts revolving around shrinking yourself, and the realization that maybe peace matters too.Because you deserve a life bigger than calorie counting.Show Notes

Losing weight on Ozempic, Wegovy, or Mounjaro but feeling bloated, constipated, and miserable? There's a reason, and a new Mayo Clinic study finally proves it.76% of patients on GLP-1s tested positive for SIBO. 91% had methane overgrowth. Dr. Kenneth Brown breaks down why these drugs turn your small intestine into a swamp, why your microbiome decides if the drug even works, and the exact protocol to fix it without quitting the medication.If you're on a GLP-1 or thinking about it, watch this first.

Welcome to Quick Hits — where we bring you the most impactful moments from past episodes in under 15 minutes. Today's clip comes from one of our most replayed conversations. If you want the full episode, check the link in the description below. Listen to the full episode here. How can GLP-1s like Ozempic truly transform weight management and wellness—and what makes them so controversial? Dr. Gus Vickery, who specializes in total body and mind optimization, dives deep into how these groundbreaking treatments are revolutionizing weight management, nutrition, and even menopause. Why are they causing such a stir, and are they truly the game-changers they claim to be? Join us as we explore the intricate relationship between GLP-1 therapy and nutritional sufficiency. Can optimizing your diet really help reduce medication dosages? What role do protein intake and exercise play in preserving muscle mass during weight loss? Dr. Vickery unravels these mysteries and more. The challenges of menopause, particularly weight gain, are also on the table. How can GLP-1 receptor agonists assist in managing hormonal shifts and inflammation? Are these medications the key to achieving sustainable health and wellness for women in midlife? In this episode, we uncover: How GLP-1 medications can revolutionize your weight management strategy. Why nutritional sufficiency is crucial for reducing medication dosages. How to optimize protein intake and exercise to preserve muscle mass. The impact of GLP-1 therapy on menopause-related weight gain and hormonal balance. How to support digestive health and nutrient absorption through enzymes, mindfulness, and supplements. Tune in to uncover the secrets to achieving a balanced, healthy lifestyle. Dr. Vickery's insights will leave you informed and inspired to take charge of your health journey. Don't miss this enlightening episode! Visit Dr. Gus Vickery's website: https://www.drgusvickery.com/     Sponsors Get 20% off your Cozy Earth Bed Sheet with coupon code HORMONES Join our new Women's Peptide Weight loss Program and get prescription based glp1s for an affordable price.     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?We dig into:Lilly's decision to stop disclosing its Phase 1 pipelineThe Camurus fluid crystal technology deal and what it means for long-acting GLP-1sEloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicineHow eloralintide compares to Novo Nordisk's cagrilintideWhy the future of obesity treatment is a toolbox, not a scoreboardThe access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gapsRetatrutide, quintuple agonists, and what's coming out of ADA 2026If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.

In this episode of Muscles by Brussels Radio, Ben sits down with Dr. Angie Sadeghi for an in-depth conversation on GLP-1 medications, gut health, digestion, fiber, and the growing confusion surrounding modern nutrition advice.Dr. Sadeghi explains how medications like Ozempic and Mounjaro actually work, why they've been so effective for appetite regulation and metabolic health, and what the research really says about concerns like muscle loss and long-term safety. The discussion also dives into insulin resistance, intramuscular fat, and why she believes many people have been misled about carbohydrates and fiber for years.Ben and Dr. Sadeghi explore why most Americans are severely lacking in fiber intake, the differences between soluble and insoluble fiber, and how gut health is often oversimplified online. They also discuss probiotics, fermented foods, microbiome testing, digestive discomfort during transitions to plant-based eating, and why Dr. Sadeghi no longer recommends the FODMAP diet for most patients.Throughout the conversation, Dr. Sadeghi shares practical insights from years of clinical experience helping patients improve their digestion, body composition, metabolic health, and long-term quality of life.

GLP-1 weight loss is about so much more than just the number on the scale.If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and feeling emotionally overwhelmed, anxious, conflicted, or even surprised by how much this journey is affecting your mindset—you are not alone.In this episode, Registered Dietitian and GLP-1 expert Gianna dives into the mental and emotional side of GLP-1 weight loss that almost nobody talks about.We're covering:How GLP-1 medications can change your relationship with foodWhat “food noise” is and why reduced food thoughts can feel emotionalWhy body image struggles don't automatically disappear with weight lossThe pressure of social media transformation cultureFear of weight regain and “what if this stops working?” thoughtsWhy needing a GLP-1 does not mean you failedIdentity shifts that can happen during major body changesHow to build a healthier mindset around sustainable weight lossWhether you're newly starting Ozempic, Wegovy, Mounjaro, or Zepbound—or deep into your GLP-1 journey—this episode is a reminder that your mental health matters too.Because sustainable health is not just about shrinking your body. It's about supporting your whole self.

In this episode, we break down the science behind GLP-1 medications including Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, and tirzepatide. Learn how GLP-1 weight loss medications work, their role in appetite suppression, insulin regulation, metabolic health, obesity treatment, and type 2 diabetes management.This evidence-based discussion explores GLP-1 benefits, side effects, muscle loss concerns, weight regain after stopping medication, nutrition considerations, digestion, metabolic adaptation, and sustainable wellness strategies. If you're considering GLP-1 medications or simply want a smarter conversation about obesity medicine, weight loss, longevity, and metabolic health, this episode delivers a clinically grounded wellness perspective. Disclaimer: This podcast is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The views shared are intended to support informed wellness conversations and should not replace individualized guidance from your physician or qualified healthcare provider. Always consult your healthcare team before making decisions regarding medications, treatment, nutrition, or health management.

EVEN MORE about this episode!What if the symptoms you're experiencing aren't the real problem—but clues pointing to a deeper root cause?In this episode, Julie Ryan performs live intuitive scans and energetic healings for callers around the world, uncovering hidden factors behind chronic health challenges, emotional struggles, and spiritual questions.From thyroid concerns in Greece and diabetes complications in Missouri to chronic anemia in England and a hearing-related tumor in California, Julie uses her medical intuitive abilities to identify energetic and physical imbalances while providing practical wellness guidance.You'll also witness powerful spirit communication, emotional healing after loss, support for a child recovering from brain surgeries, insights for a puppy experiencing seizures, and guidance for a caller hoping to avoid a second shoulder surgery. Along the way, Julie demonstrates how physical symptoms, emotional experiences, and spiritual growth are often more connected than we realize.Whether you're seeking healing, hope, or simply curious about what's possible when intuition meets wellness, this episode offers powerful insights into the hidden causes behind many of life's most challenging situations.Episode Chapters:(0:00:00) - Welcome and Thyroid/Pineal Gland Scan: Maria from Greece(0:05:03) - Type 2 Diabetes, Mounjaro, and the Keto Alternative: Connie from Missouri(0:09:05) - Schwannoma Tumor and Hearing Loss: Karen from California(0:19:58) - Sleep, Hormones, and BEAM Minerals: Judy from Florida(0:24:34) - Spirit Connection and Intuition: Sahar from Sweden(0:33:33) - Shoulder Surgery and Physical Therapy: Ryan from North Carolina(0:44:19) - Free Class Giveaway Winner Announced(0:47:29) - Puppy Seizures and Vaccine Reactions: Jessica from Maine(0:37:28) - Processing Grief: Ana and Her Father Antonio(0:53:36) - Chronic Anemia and Hormonal Healing: Anastasia from England(0:57:38) - Post-Brain Surgery Recovery: Karen and Her Son Kristoff from Phoenix➡️ Subscribe to Ask Julie Ryan YouTube➡️ Julie's Intuitive Trainings✏️ Ask Julie a Question!

President Trump uses a wide-ranging White House cabinet meeting to tout his administration's record, press Iran to make a deal, address energy concerns, and respond to the latest security scare near the White House. Former Attorney General Pam Bondi reveals she is being treated for thyroid cancer as Axios reports she is returning to the Trump administration as a liaison on the president's science and technology advisory council. A new Cleveland Clinic study finds GLP-1 drugs like Ozempic and Mounjaro are associated with slower progression in several major cancers, though researchers caution the findings do not prove the drugs caused the improved outcomes. NASA announces a new round of lunar missions and private-sector contracts aimed at testing the landers, vehicles, cargo systems, and survival infrastructure needed to return astronauts to the Moon and eventually reach Mars.   SelectQuote: Compare top‑rated life insurance options. Visit https://SelectQuote.com/megyn to get the right coverage at the right price.   Cozy Earth: This Memorial Day, visit https://www.CozyEarth.com & Use code MEGYN for up to 30% off Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 medications are changing the conversation around weight loss, metabolism, and women's health. But are we asking the right questions about long-term health?In this solo episode, Dr. Mindy Pelz breaks down the science behind GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, including what they do well, where concerns are emerging, and how fasting mimics many of the same metabolic benefits naturally.Dr. Mindy explores: • The connection between GLP-1 drugs and muscle loss • Why women over 40 need to think differently about metabolism • New research linking GLP-1s to declining bone density • How fasting impacts glucagon, ketones, and fat burning • The importance of protein, refeeding, and resistance training • Why metabolic flexibility matters more than rapid weight loss • Natural ways to stimulate your body's own GLP-1 productionThis episode is not about fear or shame. It's about helping you understand your options so you can make informed decisions for your body, your hormones, and your long-term health.For more resources related to today's episode, visit the podcast episode page: https://www.drmindypelz.com/ep341Connect with Dr. Mindy:Join Reset AcademyWatch the episodes on YouTubeFollow Dr. Mindy on InstagramSubscribe to Dr. Mindy's newsletterDisclaimer: This podcast is intended for educational and informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making changes to your diet, fasting routine, or lifestyle.

Constipation is a huge pain in the ass...  and if you're not having at least 1 to 2 bowel movements a day, you're on the "constipation spectrum." Long term opioid use, antidepressants, anti-anxiety medications, and the newer weight loss drugs like Ozempic, Wegovy, and Mounjaro all slow your gut and put you on the same path that killed Elvis Presley.  So does chronic stress, mold exposure, parasites, and the kind of inflammation that drives most cases of IBS, Crohn's, and ulcerative colitis.   TOPICS DISCUSSED: Defining constipation What actually causes it Why doctors miss the root cause The risks of long term constipation  How to fix constipation naturally   If you have Crohn's, Colitis or Diverticulitis, be sure to check out my second podcast: Reversing Crohn's and Colitis Naturally.   Leave us a Review: https://www.reversablepod.com/review   Need help with your gut? Visit my website gutsolution.ca to join a program: Get help now   Contact us: reversablepod.com/tips    FIND ME ON SOCIAL MEDIA: Instagram  Facebook  YouTube

We kick this one off the way we always do — just talking. Paul's lupus is somehow in the best shape it's ever been despite a stretch of travel, stress, and general chaos, which honestly tracks.He also got a new puppy named Charlie — a supposedly golden retriever who came out black, so there are some questions there. I'm reading my first fiction book in years (Dungeon Crawler Carl, it's actually great), heading to Vancouver to see my girlfriend, and planning a trip back to Connecticut to see family and let my mom dye my hair icy blonde. Normal stuff.Then we get into the actual topic: GLP-1 medications. These things are everywhere right now — Ozempic, Wegovy, Mounjaro — and whether you're curious, currently using one, or coaching someone who is, this episode is worth your time. Paul did his research (he called it extensive, I'll let you be the judge), and we break down what GLP-1s actually are, what glucagon-like peptide-1 does in the body, and why these medications work across multiple pathways — not just appetite suppression.We talk about who actually benefits from GLP-1s, because it's not a blanket answer. We get into food noise — that constant mental chatter around food that a lot of people don't even realize they have until it goes quiet — and why that alone can be life-changing for certain people. We also get real about the risks, the cost reality (most people are paying out of pocket), the side effects, and what the research actually shows versus what's being hyped on social media.The part I think matters most: what happens when you come off them. This is where lifestyle, meal structure, and habits become non-negotiable. The medication quiets hunger — it doesn't build the skills. That part is still on you. We talk through how we approach this with our own clients and what the off-ramp actually looks like when it's done right.Paul's IG: @paulbuonoChapters00:00 Introduction and Personal Updates07:27 Understanding GOP-1 Medications20:06 Who Can Benefit from GOP-1s?22:27 The Importance of Lifestyle Changes with GOP-1s26:25 Understanding Food Noise and Its Implications27:28 Risks and Considerations of GLP-1 Medications29:53 When to Consider Coming Off GLP-1 Medications32:53 Side Effects and Management of GLP-1 Medications36:42 Preparing for Life After GLP-1 Medications42:24 Personal Updates and Future Plans

How did Ozempic, Prozac, & Viagra get their names?... It's the wild world of drug-naming.Now is the perfect time to ask your landlord to cut your rent… We got the receipts & playbook.Google's Search Bar is history's most profitable feature… But last week it got plastic surgery.Plus, the hot new vacation trend is lights-off… Dark Sky Vacations have never been brighter.$GOOG $NVO $MARNEWSLETTER:https://tboypod.com/newsletter OUR 2ND SHOW:Want more business storytelling from us? Check our weekly deepdive show, The Best Idea Yet: The untold origin story of the products you're obsessed with. Listen for free to The Best Idea Yet: https://wondery.com/links/the-best-idea-yet/NEW LISTENERSFill out our 2 minute survey: https://qualtricsxm88y5r986q.qualtrics.com/jfe/form/SV_dp1FDYiJgt6lHy6GET ON THE POD: Submit a shoutout or fact: https://tboypod.com/shoutouts SOCIALS:Instagram: https://www.instagram.com/tboypod TikTok: https://www.tiktok.com/@tboypodYouTube: https://www.youtube.com/@tboypod Linkedin (Nick): https://www.linkedin.com/in/nicolas-martell/Linkedin (Jack): https://www.linkedin.com/in/jack-crivici-kramer/Anything else: https://tboypod.com/ About Us: The daily pop-biz news show making today's top stories your business. Formerly known as Robinhood Snacks, The Best One Yet is hosted by Jack Crivici-Kramer & Nick Martell. Hosted on Acast. See acast.com/privacy for more information.

A.M. Edition for May 22. The U.S. puts arms sales to Taiwan on hold, saying the munitions and arms are needed for the war with Iran. Plus, weight-loss drugs like WeGovy and Mounjaro show a surprising ability to stall cancer. And WSJ's Laura Cooper details how bourbon distillers are facing a hangover as more Americans pinch pennies and join the ranks of the sober-curious. Daniel Bach hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Patrick Bet-David and Dr Paul Saladino react to Charles Barkley's claim that he dropped about 85 pounds on a GLP‑1 drug similar to Mounjaro, going from the mid 350s down to the 260s in his early 60s. They acknowledge that for someone who will not change diet or lifestyle, getting 80 pounds off with a GLP‑1 is almost certainly safer than staying morbidly obese, but warn that these drugs were never meant to replace real food and movement and will likely need to be taken for life to keep the weight off.

What happens when a doctor starts questioning the very system he was trained in? In this eye-opening and deeply important conversation, Darin Olien sits down with physician and metabolic health expert Dr. Dan Reardon to unpack the exploding GLP-1 weight loss drug phenomenon, the collapse of foundational health principles, and the dangerous trend of masking chronic disease instead of addressing root causes. Together, they dive into protein myths, obesity culture, pharmaceutical incentives, body positivity, metabolic dysfunction, chronic disease, and the growing "Wild West" of weight-loss injections like semaglutide and Mounjaro. But this conversation goes much deeper than weight loss. Dr. Reardon reveals his revolutionary focus on "deprescribing" medications—helping patients safely come off statins, blood pressure medications, psychiatric drugs, and GLP-1 injections by restoring the body's innate healing systems. This episode is a powerful exploration of personal sovereignty, metabolic health, medical integrity, and why the human body may be far more intelligent than modern medicine gives it credit for. What You'll Learn Why the current protein obsession may be misunderstood How the body recycles amino acids and adapts to exercise The hidden problems with ultra-high protein consumption Why GLP-1 drugs like semaglutide and Mounjaro are raising serious concerns The cultural shift from body positivity to weight-loss injections The pharmaceutical industry's incentives around obesity medications Why most people using GLP-1 drugs are not changing their lifestyle habits The side effects associated with semaglutide and related drugs How chronic disease is often treated symptomatically instead of at the root cause Why Dr. Reardon focuses on "deprescribing" medications The importance of metabolic health and foundational lifestyle medicine How modern medicine often ignores why symptoms are happening in the first place Chapters 00:00:03 – Welcome to SuperLife 00:00:32 – Sponsor: Manna Vitality and frequency-based wellness 00:02:00 – Introducing Dr. Dan Reardon and the focus of today's conversation 00:02:39 – Protein myths and amino acid recycling in the body 00:03:00 – GLP-1 injections, semaglutide, and the weight-loss drug explosion 00:03:38 – Pancreatitis, gallbladder disease, bone loss, and hidden side effects 00:04:00 – Dr. Reardon's mission to "deprescribe" medications 00:04:22 – Why symptoms and inflammation often exist for a reason 00:04:45 – Darin and Dan reconnect after more than a decade 00:05:39 – Their original conversation about protein and muscle breakdown 00:06:11 – How the body recycles amino acids instead of wasting them 00:06:59 – Questioning mainstream protein requirements 00:08:00 – Plants as the original source of amino acids 00:08:27 – Why protein discussions remain controversial 00:08:46 – Appetite regulation, exercise, and protein utilization 00:09:27 – The flipped food pyramid and rising protein recommendations 00:10:11 – Darin critiques the meat-heavy food system 00:11:05 – Subsidized meat production and processed food systems 00:11:54 – Environmental impacts of increased protein consumption 00:12:15 – Longevity science and the dangers of excess protein intake 00:13:17 – Cancer risk, mortality, and overconsumption of protein 00:13:47 – The absurdity of protein-fortified processed foods 00:14:17 – Observing GLP-1 users still eating ultra-processed foods 00:15:04 – Society abandoning foundational health principles 00:15:50 – The body's natural GLP-1 mechanisms through movement and nutrition 00:17:08 – How semaglutide was originally developed 00:18:00 – Why injected GLP-1 drugs are not "natural" GLP-1 00:19:13 – Softening pharmaceutical language to increase acceptance 00:20:00 – The "Wild West" rollout of GLP-1 medications in the UK 00:20:33 – Government incentives pushing doctors to prescribe GLP-1 drugs 00:21:24 – Weight regain and muscle loss after stopping the injections 00:22:04 – The lack of transparency around side effects 00:22:15 – Pancreatitis, gallbladder disease, and long-term bone density concerns 00:22:58 – "Yo-yo injectors" using semaglutide for weddings and vacations 00:23:29 – Pharmaceutical culture prioritizing profit over long-term health 00:24:26 – Emotional vulnerability and the appeal of "miracle" weight-loss drugs 00:25:03 – Trusting authority figures without informed consent 00:25:34 – Why behavioral support often fails after GLP-1 treatment 00:26:07 – Sponsor: Tru Niagen and cellular NAD+ support 00:28:33 – Most people simply eat less junk food—not healthier food 00:29:00 – Why physicians struggle to keep up with rapidly changing medicine 00:30:10 – The pressure doctors face from patients demanding GLP-1 prescriptions 00:31:11 – Traditional uses for GLP-1 medications in diabetes care 00:31:36 – Why many experienced physicians refuse to prescribe these drugs 00:31:55 – Online pharmacies and supermarkets selling injections directly 00:32:17 – Doctors are not trained in emotional eating or lifestyle coaching 00:33:04 – Younger doctors inheriting pharmaceutical-driven systems 00:34:00 – Acknowledging cases where GLP-1 drugs may genuinely help 00:34:26 – The widespread abuse of semaglutide medications 00:35:18 – The changing culture inside medical schools and training systems 00:36:12 – Circumventing medical oversight through online prescriptions 00:37:17 – The disappearance of the body positivity movement 00:38:04 – Society normalizing obesity before introducing weight-loss injections 00:39:06 – Darin reflects on self-worth, consciousness, and the human body 00:40:15 – Loving people without confusing identity with physical health struggles 00:41:17 – Supporting people biologically rather than shaming them emotionally 00:42:30 – Manufactured health crises and systemic manipulation 00:43:17 – Darin and Dan discuss Fatal Conveniences and societal deception 00:44:11 – Questioning systems while helping people reclaim health sovereignty 00:45:12 – Why foundational health habits still matter most 00:45:51 – The psychological value of struggle, resilience, and achievement 00:46:50 – Human resilience and ancestral survival 00:47:19 – Resistance training and building emotional strength 00:47:44 – Dr. Reardon's current focus on deprescribing medications 00:48:20 – Helping patients improve metabolic health naturally 00:49:00 – Interpreting modern bloodwork and health testing 00:49:46 – Why patients don't want to return to medications once they heal 00:50:13 – Helping the body "come back online" naturally 00:50:42 – The body's intelligence and adaptive inflammatory responses 00:51:44 – Suppressing symptoms without resolving root causes 00:52:17 – High blood pressure as a signal—not just a diagnosis 00:53:04 – Investigating why symptoms happen instead of masking them 00:53:46 – Medicine as detective work 00:54:14 – Building a medical practice aligned with integrity 00:55:10 – Why healthcare systems need course correction 00:56:23 – Final reflections on truth, integrity, and helping people thrive Join the Superlife Community Get Darin's deeper wellness breakdowns — beyond social media restrictions: Weekly voice notes Ingredient deep dives Wellness challenges Energy + consciousness tools Community accountability Extended episodes Join for $7.49/month → https://patreon.com/darinolien     Find More from Dr. Dan Reardon Website: https://www.drdanreardon.com/  Instagram: @drdanreardon Get Your GLP1 Timeline Tool: Website Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences Key Takeaway "The human body is not broken: it is adaptive, intelligent, and constantly responding to the environment it's placed in. Modern medicine often suppresses symptoms without asking why they exist in the first place. Real healing begins when we stop chasing shortcuts, start addressing root causes, and create the conditions for the body to do what it was designed to do all along: heal, regulate, and thrive."

Three new GLP-1 studies, why every food is suddenly "high protein," the Bethenny Frankel shoe drama blowing up Instagram, and why I'm on a ketamine table as you listen. Three new studies just shifted the GLP-1 conversation, and not in the direction women have been hearing about. Chalene digs into what's actually happening to muscle and bone density, why the rebound after coming off matters more than anyone's talking about, and the three questions every woman on Ozempic, Wegovy, Mounjaro, or Zepbound should bring to her next doctor's appointment. She also gets into why every grocery aisle suddenly screams "high protein," and why this whole moment is starting to feel suspiciously like the Snackwell cookie era. There's a simple protein target that works without tracking macros, and Chalene walks through how she's using it. Then she breaks down the Bethenny Frankel shoe drama that took over Instagram this week. What the shoe brand founder got wrong, what Bethenny got wrong, and the rules of brand partnerships that almost nobody outside the influencer world understands. Finally, a personal update. As you're listening to this, Chalene is on the table for another medically supervised ketamine treatment with Dr. Andrew Levinson. She shares why she went back for a third session, what the last journey taught her about control, and who this kind of work is really for.  

This episode is brought to you by LMNT, Fatty15, and Caldera Lab. What if obesity isn't a willpower problem at all? In this deeply eye-opening conversation, Chase sits down with bariatric surgeon and obesity medicine specialist Dr. Betsy Dovec, MD to unpack the science, psychology, and stigma surrounding obesity in America today. From GLP-1 medications like Ozempic and Mounjaro to bariatric surgery, emotional eating, food addiction, metabolic dysfunction, and the failures of fad diets, this episode challenges nearly everything we think we know about weight loss. Whether you're someone struggling with weight, supporting a loved one, or simply curious about the future of metabolic health, this conversation offers nuance, compassion, and hard truths that could completely reshape your understanding of obesity and modern wellness. IN THIS EPISODE YOU WILL LEARN Why Dr. Dovec believes obesity is primarily biological — not a lack of discipline The hidden role trauma and emotional safety can play in weight gain How bariatric surgery changes hormones, hunger, and "food noise" The truth about Ozempic, Wegovy, Mounjaro, and long-term GLP-1 use Why most people regain weight after stopping GLP-1 medications The difference between gastric bypass and gastric sleeve surgery Why visceral fat is more dangerous than the number on the scale How obesity impacts cardiovascular disease, diabetes, fatty liver, and longevity The surprising reason BMI may be one of the worst health markers Why women account for nearly 85% of bariatric surgery patients How sugar and ultra-processed foods are driving the obesity epidemic What long-term success after bariatric surgery actually requires The psychological side of transformation and behavior change Why "food noise" may be one of the biggest hidden barriers to weight loss How bariatric surgery and GLP-1s may work best together The future of weight loss medicine, surgery, and employer healthcare coverage Follow Betsy @drdovec Follow Chase @chase_chewning ----- 00:00 — Is Obesity a Willpower Problem or a Biological Problem? 04:40 — When Should Someone Consider Bariatric Surgery? 08:00 — Trauma, Emotional Eating & Feeling Unsafe in the Body 14:20 — Why Obesity Is More Complex Than Calories In vs. Calories Out 15:40 — Why Men Wait Too Long to Address Their Health 17:42 — Bariatric Surgery Misconceptions & Who Actually Qualifies 19:00 — How Bariatric Surgery Immediately Improves Diabetes 20:40 — Why BMI Is a Flawed Health Marker 23:00 — Visceral Fat, Fatty Liver Disease & Sugar Addiction 27:00 — Is Obesity Truly Reversible? 29:20 — Why Gastric Bypass Is Still the "Gold Standard" 31:55 — How Gastric Bypass Surgery Actually Works 35:00 — Nutrient Absorption & Supplements After Surgery 37:00 — What Daily Life Looks Like After Bariatric Surgery 42:00 — Food Noise, Hunger Hormones & Feeling Full for the First Time 45:00 — Risks, Complications & Safety of Bariatric Surgery 49:45 — Insurance Coverage, Costs & Why Employers Are Paying for Surgery 54:30 — Long-Term Outcomes & Lifespan Benefits 57:00 — Eating Disorders, Addiction Transfer & Alcohol After Surgery 01:02:00 — Why Dr. Dovec Prioritizes Lower Carb Nutrition 01:05:00 — The Ethics of the Weight Loss Industry 01:10:00 — GLP-1 Medications vs. Bariatric Surgery 01:15:00 — Why Bariatric Surgery Numbers Are Falling 01:20:00 — Rapid Fire: Ozempic, Body Positivity & Discipline 01:25:00 — Parenting, Childhood Obesity & The Future of Weight Loss 01:29:00 — What "Ever Forward" Means to Dr. Dovec ----- Episode resources: Watch and subscribe on YouTube Learn more at BodyByBariatrics.com FREE variety sample pack of LMNT electrolytes  Additional 15% off Fatty15 with code EVERFORWARD 20% off Caldera Lab men's skincare with code EVERFORWARD